Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2.
A family with three cases of macroglobulinaemia of undetermined significance (MGUS), and one case each of immunoblastic lymphoma, Waldentröm's macroglobulinaemia and multiple myeloma was first described 20 years ago. We have previously identified 10 out of 35 healthy family members tested whose lymphocytes produced abnormally high amounts of immunoglobulins in culture. In the present study lymphocyte subpopulations of these hyper-responders have been further characterized and lymphocyte reactivity and survival in vitro have been studied. No differences were detected in the proportions of resting B lymphocytes (CD19+) co-expressing CD5, CD10, CD11b, or CD38, and the CD4/CD8 ratio of T cells was normal before and after stimulation with pokeweed mitogen (PWM). The initial rate of response in terms of immunoglobulin production was not increased, but immunoglobulin levels continued to rise during the second week of culture whereas the production peaked at 8 days in control cultures. This was associated with significantly greater survival of lymphocytes and at 14 days surviving B cells could only be identified in samples from hyper-responders. A lymph node removed because of tuberculosis from a family member 23 years before the diagnosis of multiple myeloma showed very marked Bcl-2 expression in a B cell follicle. This was not seen in a tuberculous lymph node from an unrelated subject. Stimulated cultures from three hyper-responders tested demonstrated significantly higher retention of Bcl-2 in B cells compared with one family control and six unrelated controls. We conclude that the increased production of immunoglobulins previously observed in this family with an inherited tendency for benign and malignant B cell proliferation is the result of enhanced B cell survival, which is associated with increased expression of Bcl-2 following stimulation.
Ogmundsdóttir
H M
HM
Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society, Reykjavík. helgam@krabb.is
Sveinsdóttir
S
S
Sigfússon
A
A
Skaftadóttir
I
I
Jónasson
J G
JG
Agnarsson
B A
BA
D016175:B-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D002470:Cell Survival / Q000276:immunology; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D005434:Flow Cytometry; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000737:chemistry / Q000378:metabolism; D008213:Lymphocyte Activation; D011043:Pokeweed Mitogens / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis* / Q000737:chemistry; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013997:Time Factors; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*
D007136:Immunoglobulins; D011043:Pokeweed Mitogens; D019253:Proto-Oncogene Proteins c-bcl-2